Sorafenib is an oral multiple kinase inhibitor that inhibits proteins involved in both tumor cell proliferation and angiogenesis, or the formation of new blood vessels that support the growth of cancer cells. We are working with our partner Bayer to implement a clinical development program designed to assess sorafenib's applicability across multiple tumor types.
In thyroid cancer, the Phase 3 trial (DECISION) is designed to confirm sorafenib's efficacy as a single agent, based upon data demonstrated in Phase 2 studies. In breast cancer, the Phase 3 RESILIENCE trial is evaluating the all oral regimen of sorafenib in combination with capecitabine in patients with locally advanced or metastatic HER-2 negative breast cancer who are resistant to or have failed prior taxane and an anthracycline or for whom further anthracycline is not indicated. Late stage studies are also being conducted in liver and kidney cancer in the adjuvant setting.